Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP1011T tablets in unresectable or metastatic osteosarcoma (single-arm phase IIb)
ChiCTR2500111060Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ABP1011T in osteosarcoma (OS), sponsored by Peking University People's Hospital. Primary endpoint: Objective response rate (ORR). Started Oct 2025; status: recruiting.
02
Drugs
ABP1011T
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on ChiCTR2500111060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111060.